Philadelphia chromosome-positive (Ph+) ALL, characterized by the BCR-ABL1 fusion gene, has seen important advances through the incorporation of tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib, which are now standard components of therapy, as recommended by the NCCN [66,67,68]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.